TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03588910
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed)
Study: NCT03588910
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed)
Study: NCT00536939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, daily, until disease progression
Study: NCT03096314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single, liquid enteral dose identical in appearance and consistency to cholecalciferol administered either orally or via naso/orogastric tube.
Study: NCT02235064
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing cellulose powder of same color as experimental arm
Study: NCT00516022
Drug: Mistletoe extract
Normalized name: MISTLETOE EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug will be administered 3 times a week at home.
Study: NCT03532425
Drug: B/F/TAF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet taken orally once daily
Study: NCT01174823
Drug: placebo comparator ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile ophthalmic solution
Study: NCT01692041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml per os twice daily
Study: NCT02764762
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate oral tablets.
Study: NCT02194283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03548961
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX regimen will be administered for 6 cycles. Each cycle is 14 days followed by restaging, local surgery and concurrent chemo radiation therapy
Study: NCT02962583
Drug: Probiotic Formula
Normalized name: Probiotic Formula
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02962583
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02811510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill (no active cannabinoids)
Study: NCT02806908
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04404543
Drug: SYHA1807
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalation Cohort Administration: Orally
Study: NCT04404543
Drug: SYHA1807
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Expansion Cohort Administration: Orally
Study: NCT00946972
Drug: JNJ-38431055; Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02281448
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02281448
Drug: Contraceptives, Oral, Combined
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01071642
Drug: stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure
Study: NCT01071642
Drug: ACE/ARB stopped 24 hours before procedure and start immediately after
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure
Study: NCT04283240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02930772
Drug: BAY987516
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z46-100)
Study: NCT02805153
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00791778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Placebo arm will receive 2 matching placebo tablets twice a day and in continuous administration.
Study: NCT01082328
Drug: Kuvan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuvan® (sapropterin dihydrochloride) oral solution 20 milligram per kilogram (mg/kg) will be given once daily for 28 +/- 1 days.
Study: NCT00172198
Drug: Omegaven 10%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00957801
Drug: Testosterone injection
Normalized name: testosterone Injection
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg single IM injection
Study: NCT00957801
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel 10 mg. administered topically daily for seven days
Study: NCT00031590
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given at a dose of 1g/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Administration of cyclophosphamide will always be preceded by prehydration and Mesna (Regimen B only).
Study: NCT03956979
Drug: JM-010 group B
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: JM-010 fixed combination drug (Group B) + Placebo 1
Study: NCT03956979
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 + Placebo 2
Study: NCT00683722
Drug: Prochymal™
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of ex- vivo cultured adult human mesenchymal stem cells.
Study: NCT00683722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of excipient of Prochymal™.
Study: NCT00448266
Drug: dose dense adriamycine and cyclophosphamide
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose dense adriamycine and cyclophosphamide, Q 2 weeks
Study: NCT02124655
Drug: Essential oils
Normalized name: essential oils
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01283464
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.02% cream
Study: NCT01282684
Drug: PLX5622
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in dosage strengths of 25 mg and 100 mg with matching placebo
Study: NCT01282684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for PLX5622.
Study: NCT02224651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as solution/suspension) under fed and/ or fasted conditions.
Study: NCT02224651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as capsule) under fed and/ or fasted conditions.
Study: NCT04746287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00772590
Drug: Hyper-immune Bovine Colostrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 1800mg, twice daily
Study: NCT04103892
Drug: CLE-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of CLE-100 administered once daily
Study: NCT04103892
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of placebo administered once daily
Study: NCT02450201
Drug: Pyruvate
Normalized name: Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01498796
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01498796
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00722358
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral, Q 12h, 3/5 days~Panel 1: matching placebo~Panel 2: matching placebo~Panel 3: matching placebo
Study: NCT03629262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of placebo and sufentanil (1.25 ug/m), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
Study: NCT00655993
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg po daily
Study: NCT00929370
Drug: Glycine Transporter-1 inhibitor
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GSK1018921 is a potent and selective inhibitor of the glycine transporter-1 (GlyT-1).
Study: NCT03337087
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03337087
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04505657
Drug: celecoxib plus lidocaine
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
Study: NCT04505657
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +Sterile water 4 puffs during the procedure
Study: NCT00663416
Drug: NTx™-265: rhCG, then rEPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: * rhCG 10,000 IU, SC, on Day 1, 3, and 5 of study participation, then~* rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation
Study: NCT02992041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of 0 mg of VVZ-149
Study: NCT04079647
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive immunotherapy for cancer treatment
Study: NCT01514981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo on study day 1.
Study: NCT02859337
Drug: UPA-ECx1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 30mg of UPA-based EC
Study: NCT02859337
Drug: UPA-ECx2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 60mg of UPA-based EC
Study: NCT03077477
Drug: AMXT 1501
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment will be provided in tablet form; each containing 128 mg AMXT 1501 dicaprate salt, 80 mg of which is AMXT 1501 freebase (active drug), plus excipients and are orally administered.
Study: NCT03077477
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference Therapy, Dose and Route of Administration:~Placebo Tablets, orally administered
Study: NCT01486446
Drug: XPF-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
Study: NCT01486446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
Study: NCT00523848
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT02499848
Drug: PRX302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single prostate cancer lesion injected with PRX302.
Study: NCT01938092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01598363
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral, Day 1 and Day 10
Study: NCT00848718
Drug: corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered PO twice a day (BID) on Days 1-3 of each 21-day cycle
Study: NCT00824200
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin placebo
Study: NCT01611883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match ezetimibe orally once daily for 24 weeks.
Study: NCT00466245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 0.5mL subcutaneous injections, separated by 28 days
Study: NCT02644954
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug twice daily given in the intervention arm to patients of moderate psoriasis
Study: NCT03373877
Drug: PU-H71
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PU-H71 treatments will be administered by IV infusion on days 1, 8, and 15 of each 28-day cycle.
Study: NCT02367651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets matching the 200 mg and 400 mg pazopanib tablets
Study: NCT03764774
Drug: LY3463251
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03764774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02596360
Drug: Pulmodexane® 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
Study: NCT02596360
Drug: lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
Study: NCT02021929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02180529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04203342
Drug: Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo to treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
Study: NCT02151851
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Active substance: Methotrexate~* Pharmaceutical form: Tablet~* Concentration: Maximum dose 10 mg per week~* Route of administration: Oral
Study: NCT02143505
Drug: Ca plus vit D
Approvals — FDA: no, EMA: no, PMDA: no
Description: elemental calcium 1200mg/d plus vitamin D3 250 IU/d daily supplements
Study: NCT00611923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take a lactose capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
Study: NCT01080638
Drug: glycoprotein IIb/IIIa inhibitor (abciximab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg body weight,continus 12hrs-0.125ug/kg per minute(maximum: 10ug/min)
Study: NCT03667222
Drug: minocycline topical gel
Normalized name: minocycline Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily administration of BPX-04 minocycline gel for 12 weeks
Study: NCT01024504
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine at the dose of 1500 mg/m2 per os at days 1 to 7 every 2 weeks for a maximum of 12 consecutive cycles
Study: NCT00086684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo capsule 3 times a day (morning, afternoon and evening) for 24 weeks
Study: NCT01113437
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab or placebo by subcutaneous injections, at 4 weekly or 2 weekly intervals.~Dosage is according to manufacturer's guidance and calculated based on body weight and total serum IgE.
Study: NCT02547428
Drug: CTN SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTN SR tablets, daily, Orally.
Study: NCT02547428
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching-placebo tablets daily, orally.
Study: NCT01056783
Drug: OC000459
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC000459 100mg, twice daily, tablet
Study: NCT01056783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to match OC000459 tablets, twice daily
Study: NCT00381082
Drug: 1) MOOV Head Lice Treatment (Ego Pharmaceutical).
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00381082
Drug: 3) KP24 Medicated Foam (Nelson Laboratories)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04651855
Drug: Mesenchymal stem cells isolated from Wharton's jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal administration of mesenchymal stem cells
Study: NCT04070001
Drug: 400 Mg Ibuprofen
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-dose 400-mg ibuprofen 1-hour before elastomeric separator placement
Study: NCT02462590
Drug: L. rhamnosus GG - Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
Study: NCT04444011
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic
Study: NCT01185678
Drug: Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet per day, orally, 28 tablets per cycle, during three consecutive cycles.
Study: NCT02745431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00406367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
Study: NCT04022057
Drug: Dextrose 5
Normalized name: Dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham Injection
Study: NCT04483830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: an oral dose of 2 capsules each day for 21 days
Study: NCT01412567
Drug: Vaccine+Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS placebo intramuscularly immediately after birth
Study: NCT00702767
Drug: INTRALIPIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: INTRAVENOUS FAT EMULSIONS
Study: NCT01567774
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: os, 10 mg, once per day, for 30 days
Study: NCT02962492
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
Study: NCT01702623
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01591135
Drug: Paclitaxel plus 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ﬂuorouracil 300 mg/m2, d1-4, continuous infusion for 96 hours and paclitaxel 50 mg/m2 over 3 hours, d1 (week 1, week 2, week 3, week 4 and week 5); 5-ﬂuorouracil 600 mg/m2/d d1-3 and paclitaxel 175 mg/m2 d1(week 9 and week 13).
Study: NCT01591135
Drug: Cisplatin plus 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
Study: NCT03150719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to TEZ/IVA fixed-dose combination tablet.
Study: NCT03150719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to IVA tablet.
Study: NCT00384618
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03657420
Drug: ABI-009
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-009 is an mTOR inhibitor. This pathway is believed to be overactive in multiple myeloma.
Study: NCT03005704
Drug: Antiplatelet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be treated with ticagrelor in combination with acetylsalicylic acid for five days. Ticagrelor will be administered at a loading dose of 180 mg, followed by 90 mg twice daily maintenance dose. Acetylsalicylic acid will be administered at a dose of 81 mg daily.
Study: NCT00869622
Drug: Placebo + Calcium and Vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill + calcium 1200mgs/day and vitamin d at least 800IU
Study: NCT01107522
Drug: CTO and Temodar®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of CTO daily for 28 day cycles, starting dose of CTO = 219 mg/m2.~Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle.~Expansion Cohort of 6 patients on fixed dose of 600mg CTO/day Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle